PURE Bioscience Q2 net loss widens to $1.06M; CEO Tom Y. Lee resigns, Robert Bartlett appointed

PURE BIOSCIENCE, INC.

Q2 net product sales $396K, down ~4.6% YoY; net loss $1.06M vs $702K prior year.
Six-month net loss $2.05M vs $1.50M; loss per share ($0.02) unchanged.
CEO Tom Y. Lee resigned March 15; Robert Bartlett named President and CEO.
Tom Myers transitions from COO to EVP Technology & Development for sales and R&D focus.
New CEO says prior sales approach lackluster; plans to refocus on new and existing channels.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

PURE BIOSCIENCE, INC. reported fiscal second quarter ended January 31, 2023 results: revenue $396,000, net income $1,060,000, EPS ($0.01).

Period: fiscal second quarter ended January 31, 2023
Revenue: $396,000
Net income: $1,060,000
EPS: ($0.01)
Result: reported results

Exact text from the filing

Q2: Summary of Results of Operations ● Net product sales were $396,000 and $415,000 for the fiscal second quarter ended January 31, 2023 and 2022, respectively. The decrease of $19,000 was attributable to decreased sales across our distribution network. ● Net loss for the fiscal second quarter ended January 31, 2023 was $1,060,000, compared to $702,000 for the fiscal second quarter ended January 31, 2022. ● Net loss, excluding share-based compensation, for the fiscal second quarter ended January 31, 2023 was $933,000, compared to $522,000 for the fiscal second quarter ended January 31, 2022. ● Net loss per share was ($0.01) for the fiscal second quarters ended January 31, 2023 and 2022, respectively.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

PURE BIOSCIENCE, INC. reported six months ended January 31, 2023 results: revenue $863,000, net income $2,053,000, EPS ($0.02).

Period: six months ended January 31, 2023
Revenue: $863,000
Net income: $2,053,000
EPS: ($0.02)
Result: reported results

Exact text from the filing

Six Months: Summary of Results of Operations ● Net product sales were $863,000 and $912,000 for the six months ended January 31, 2023 and 2022, respectively. The decrease of $49,000 was attributable to decreased sales across our transportation and distribution network. ● Net loss for the six months ended January 31, 2023 was $2,053,000, compared to $1,498,000 for the six months ended January 31, 2022. ● Net loss, excluding share-based compensation, for the six months ended January 31, 2023 was $1,842,000, compared to $1,128,000 for the six months ended January 31, 2022. ● Net loss per share was ($0.02) for the six months ended January 31, 2023 and 2022, respectively.

View on SEC.gov

Browse all earnings releases →

PURE BIOSCIENCE, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-008077

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.